Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Why Krystal Biotech (KRYS) Might Surprise This Earnings Season
by Zacks Equity Research
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
KRYSNegative Net Change
biotechs medical
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
LGNDPositive Net Change ZTSNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
ALKSNegative Net Change LGNDPositive Net Change ANIPNegative Net Change VYGRNegative Net Change
biotechs earnings
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
LGNDPositive Net Change RGENNegative Net Change ANIPNegative Net Change VYGRNegative Net Change
biotechs earnings
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
MRKNegative Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYNegative Net Change LGNDPositive Net Change SRPTNegative Net Change ANIPNegative Net Change
biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GSKNegative Net Change BMYNegative Net Change GILDNegative Net Change EDITNegative Net Change DCPHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
REGNNegative Net Change SNYPositive Net Change BAYRYNegative Net Change TSVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
NVONegative Net Change LGNDPositive Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
LGNDPositive Net Change AMRNNegative Net Change ANIPNegative Net Change VYGRNegative Net Change
biotechs earnings
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSKNegative Net Change JNJPositive Net Change ANIPNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
ALNYNegative Net Change ATRANegative Net Change ARGXNegative Net Change ANNXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
EXELNegative Net Change AMRNNegative Net Change ANIPNegative Net Change VYGRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
PFEPositive Net Change SRPTNegative Net Change ATRANegative Net Change BNTXNegative Net Change
biotechs
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
NVSPositive Net Change LLYNegative Net Change INCYNegative Net Change SNDXNegative Net Change
biotechs earnings
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNNegative Net Change PFEPositive Net Change NVONegative Net Change AMGNPositive Net Change MRNAPositive Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ALNYNegative Net Change VRTXPositive Net Change CRSPNegative Net Change ALPNPositive Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
ALNYNegative Net Change AMGNPositive Net Change EXELNegative Net Change NVAXNegative Net Change
biotechs
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
SRPTNegative Net Change ADMANegative Net Change ATRANegative Net Change ARGXNegative Net Change
biotechs
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRNegative Net Change EXELNegative Net Change SRPTNegative Net Change COLLPositive Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTNegative Net Change ARGXNegative Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYNegative Net Change JNJPositive Net Change ABBVNegative Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
SRPTNegative Net Change PBYIPositive Net Change ATRANegative Net Change ARGXNegative Net Change
biotechs
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDPositive Net Change ANIPNegative Net Change SAGENegative Net Change
biotechs medical pharmaceuticals